Sixteen Years of Data Show Biopharma R&D Returns Rebound to 7%, But Recovery Remains Concentrated in GLP-1 Therapies

Deloitte查看公司主页's flagship pharmaceutical R&D productivity series, now spanning sixteen editions, has documented a striking recovery in the industry's internal rate of return (IRR), which reached 7.0% in 2025 — the highest level since 2014. Yet the analysis, authored as a retrospective by the series' outgoing leader, cautions that this rebound is fragile and heavily concentrated in a single therapeutic area, rather than reflecting a systemic transformation of the R&D model.

The dataset, described as "one of the most-cited barometers of biopharma's capacity to create value from scientific and clinical innovation," traces a story in three acts. When the analysis began in 2010, the average IRR for the world's largest biopharma companies stood at 10.1%, reflecting what the author calls "the blockbuster era." Over the following nine years, the IRR fell almost every year, reaching 1.5% by 2019 — a figure so low that the tenth-anniversary report asked "bluntly, whether the current R&D model was viable at all."

The decline was driven by what the author terms a "scissors dynamic": escalating clinical development costs, shrinking peak sales forecasts as markets fragmented into smaller and more specialised patient populations, and lengthening cycle times. The average cost per asset rose from $1.19 billion in 2010 to nearly $2 billion by 2019.

The Pandemic Bump and Its Aftermath

COVID-19 briefly reversed the trajectory. In 2021, the combined cohort's IRR surged to 6.8%, the highest level since 2014, as average cycle times fell and forecast peak sales jumped back above $500 million per asset. However, the author describes this as a temporary phenomenon rather than a turning point.

In 2022, as the most valuable COVID-19 assets were approved and moved into commercial portfolios — and therefore out of the late-stage pipeline model — the IRR collapsed to 1.2%, "the lowest figure in the history of the series." The author characterises this as "a statistical artefact as much as a genuine productivity collapse," but argues it illustrated that "the industry had not yet internalised the lessons of COVID-19 development speed."

"The 2022 result was a sobering reminder that external disruption is not a substitute for systemic change," the author writes.

A Fragile Recovery Driven by GLP-1 Therapies

The last two years have brought "genuine, if fragile, cause for optimism." The IRR recovered to 4.3% in 2023 and reached 7.0% in 2025, driven by a wave of high-value late-stage assets in obesity (搜索)搜索该疾病, diabetes (搜索)搜索该疾病, and Alzheimer's disease (搜索)搜索该疾病. GLP-1 (搜索)搜索该靶点 therapies have reshaped the industry's financial landscape, with two companies in the 2025 cohort projecting average peak sales exceeding $2 billion per asset. The number of projected blockbusters — assets forecast to achieve peak sales above $1 billion — rose to 29 new entrants in 2024 alone.

But the author is explicit about the concentration risk: "If GLP-1 (搜索)搜索该靶点 therapies are excluded from the 2025 analysis, the IRR falls from 7.0% to 2.9%. The recovery is real, but it is not yet systemic or the result of a new model."

The Structural Cost Problem

Across sixteen years, the average cost to bring a late-stage asset from discovery to launch has nearly doubled, from $1.19 billion in 2010 to $2.67 billion in 2025 — an increase recorded across 12 of the top 20 companies. The author stresses this is "not primarily inflation," but reflects "the genuine increase in protocol complexity, complex study endpoints, companion diagnostics, the shift toward specialist and rare disease indications requiring smaller and harder-to-recruit trial populations, and the competitive intensity in therapeutic areas like oncology."

Phase III cycle times increased a further 12% in 2024, and the author warns that "until the industry finds a durable way to compress Phase III cycle times, cost management will remain a structural headwind."

External Innovation and Novel Mechanisms of Action

Two structural shifts stand out across the series. First, externally sourced innovation has become the norm. In 2021, 66% of the combined cohort's late-stage pipeline volume was projected to come from externally sourced assets, up from roughly 50% a decade earlier — though the author notes this was "an outlier representing the acquisition of COVID assets." By 2025, nearly half of all forecast revenues were expected to be generated through externally sourced innovation, transforming large-cap biopharma companies into "sophisticated integrators and developers of innovations originating elsewhere."

Second, novel mechanisms of action are the engine of value creation. The most recent analysis found that novel mechanisms of action — representing just 28% of the late-stage pipeline on average — account for 53% of projected revenue. "The premium attached to genuine therapeutic innovation is not just scientific, it is financial," the author writes, citing GLP-1 (搜索)搜索该靶点 biology and ADC engineering in oncology as examples of companies "generating disproportionate returns."

The AI Question and the Path Forward

The author offers a disciplined view of technology's role, noting that every edition of the report has identified a technology — genomics, personalised medicine, digital biomarkers, platform technologies, AI — as a potential solution to the productivity challenge, and "in each case, the technology has taken longer to translate into measurable R&D efficiency gains than the optimists anticipated."

On AI specifically, the author argues that "AI's contribution to R&D productivity will ultimately be measured in cycle time and cost, not in announcements and increasing spend." The critical question for the next five years is "whether the industry can use AI-enabled insights to reduce Phase III attrition — the single biggest driver of the cost escalation we have documented across this series."

The author also flags the patent cliff of 2025-2030 as a pressing concern, warning that "M&A alone will not solve it," as competition for high-quality external innovation intensifies. The most consistent finding across sixteen years, the author concludes, is that "the companies that invest boldly in genuine innovation, tolerate the near-term cost of doing so, and build the internal capability to translate scientific insight into clinical proof, generate the highest long-term returns. The IRR follows the science not the market."